170 related articles for article (PubMed ID: 30470990)
1. Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma.
Tucci M; Stucci LS; Mannavola F; Passarelli A; D'Oronzo S; Lospalluti L; Giudice G; Silvestris F
Clin Transl Oncol; 2019 Jul; 21(7):845-854. PubMed ID: 30470990
[TBL] [Abstract][Full Text] [Related]
2. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
[TBL] [Abstract][Full Text] [Related]
3. Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence.
van den Hout MFCM; Koster BD; Sluijter BJR; Molenkamp BG; van de Ven R; van den Eertwegh AJM; Scheper RJ; van Leeuwen PAM; van den Tol MP; de Gruijl TD
Cancer Immunol Res; 2017 Nov; 5(11):969-977. PubMed ID: 28935649
[TBL] [Abstract][Full Text] [Related]
4. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma.
Tas F; Erturk K
Int J Clin Oncol; 2019 Jun; 24(6):721-726. PubMed ID: 30788673
[TBL] [Abstract][Full Text] [Related]
5. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
6. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement.
Leiter U; Buettner PG; Bohnenberger K; Eigentler T; Meier F; Moehrle M; Breuninger H; Garbe C
Ann Surg Oncol; 2010 Jan; 17(1):129-37. PubMed ID: 19866238
[TBL] [Abstract][Full Text] [Related]
8. Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases.
Holtkamp LH; Wang S; Wilmott JS; Madore J; Vilain R; Thompson JF; Nieweg OE; Scolyer RA
Ann Surg Oncol; 2015 Sep; 22(9):2972-7. PubMed ID: 25990968
[TBL] [Abstract][Full Text] [Related]
9. Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role?
Ribero S; Osella-Abate S; Sanlorenzo M; Balagna E; Senetta R; Fierro MT; Macripò G; Macrì L; Sapino A; Quaglino P
Ann Surg Oncol; 2015; 22(6):1967-73. PubMed ID: 25388059
[TBL] [Abstract][Full Text] [Related]
10. Sentinel-node biopsy or nodal observation in melanoma.
Morton DL; Thompson JF; Cochran AJ; Mozzillo N; Elashoff R; Essner R; Nieweg OE; Roses DF; Hoekstra HJ; Karakousis CP; Reintgen DS; Coventry BJ; Glass EC; Wang HJ;
N Engl J Med; 2006 Sep; 355(13):1307-17. PubMed ID: 17005948
[TBL] [Abstract][Full Text] [Related]
11. Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.
Mozzillo N; Pasquali S; Santinami M; Testori A; Di Marzo M; Crispo A; Patuzzo R; Verrecchia F; Botti G; Montella M; Rossi CR; Caracò C
Eur J Surg Oncol; 2015 Jul; 41(7):823-9. PubMed ID: 25800935
[TBL] [Abstract][Full Text] [Related]
12. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.
Molenkamp BG; van Leeuwen PA; Meijer S; Sluijter BJ; Wijnands PG; Baars A; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2007 May; 13(10):2961-9. PubMed ID: 17504997
[TBL] [Abstract][Full Text] [Related]
13. The management of cervical lymph nodes in patients with cutaneous melanoma.
Martin RC; Shannon KF; Quinn MJ; Saw RP; Spillane AJ; Stretch JR; Colman MH; Gao K; Thompson JF
Ann Surg Oncol; 2012 Nov; 19(12):3926-32. PubMed ID: 22669449
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of cutaneous melanoma of the head and neck after negative sentinel lymph node biopsy.
Davis-Malesevich MV; Goepfert R; Kubik M; Roberts DB; Myers JN; Kupferman ME
Head Neck; 2015 Aug; 37(8):1116-21. PubMed ID: 24764188
[TBL] [Abstract][Full Text] [Related]
15. The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma.
Gipponi M; Solari N; Giovinazzo D; Queirolo P; Bertoglio S; Villa G; Gualco M; Bleidl D; Cafiero F
Anticancer Res; 2014 Jun; 34(6):3197-203. PubMed ID: 24922694
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
17. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
[TBL] [Abstract][Full Text] [Related]
18. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up.
Satzger I; Meier A; Hoy L; Völker B; Kapp A; Hauschild A; Gutzmer R
Ann Surg Oncol; 2011 Feb; 18(2):514-20. PubMed ID: 20839060
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node staging of cutaneous melanoma: predictors and outcomes.
Ellis MC; Weerasinghe R; Corless CL; Vetto JT
Am J Surg; 2010 May; 199(5):663-8. PubMed ID: 20466113
[TBL] [Abstract][Full Text] [Related]
20. [Cutaneous malignant melanoma of the head and neck with intermediate tumor thickness: the role of elective lymph node dissection for clinical stage I].
Wenzel S; Sagowski C; Neuber K; Kehrl W; Metternich FU
Laryngorhinootologie; 2003 Jan; 82(1):19-24. PubMed ID: 12548460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
